ESR1 and cancer: A higher percentage of postmenopausal women (p = 0.0157) as well as a significantly higher percentages of patients with positive estrogen receptor status (p = 0.0225) and progesterone receptor status (p = 0.0014) in cancer cells were also observed more frequently in the BCT group.